HGH Fragment 176-191
Peptiva
HGH Fragment 176-191
ISKLJUČIVO ZA IN VITRO LABORATORIJSKA ISTRAŽIVANJA.
Nije namijenjen osobnoj, kliničkoj, dijagnostičkoj ili veterinarskoj primjeni niti primjeni na ljudima ili životinjama.
Description and specifications
What is HGH Fragment 176-191?
HGH Fragment 176-191 represents the C-terminal portion of human growth hormone. It was designed to study the metabolic effects of the hormone's terminal region separately from the full protein.
Mechanism and Scientific Context
Preclinical work focuses on pathways related to fat breakdown and formation, with an attempt to distinguish them from the classical GH/IGF-1 growth axis. The exact receptor and signaling profile of the fragment is not fully elucidated.
Main Areas of Research
- lipolysis and adipocyte metabolism
- relationship between HGH structure and metabolic activity
- comparison of the fragment with whole growth hormone
- energy homeostasis in preclinical models
How to Interpret Research Data?
When reading literature, check the identity of the tested material, the type of model, and the limitations of the study. The existence of work on a molecule does not confirm the properties of this product or its batch. Findings from laboratory and animal models do not prove clinical benefit.
Available Peptiva Variants
- 5 mg · Lyophilized vial
- 5 mg · Research dispenser
Select the available variant and check its name, total content, and price. The photo is not a substitute for the declaration of the selected variant.
Format and Package Contents
Research dispenser: The variant contains a fully filled dispenser with the selected content, not just a separate replacement cartridge. The quantity indicated with the variant refers to the total declared content, not the amount per individual use.
Lyophilized vial: The variant contains lyophilized material in a vial, without a dispenser. This description does not refer to bacteriostatic water or a separate empty container.
Storage and handling conditions depend on the specific formulation and batch declaration. The packaging format does not confirm sterility, dosing precision, stability, or suitability for human or animal application.
Important Limitations
Evidence is limited and largely preclinical. Marketing claims about selective fat loss should not be considered a confirmed clinical effect.
Batch Documentation
For inquiries about available COA documentation, please contact peptivacomhr@gmail.com with the product name and LOT number if known. Availability and scope of analyses are checked for the specific batch. A COA does not inherently prove sterility or suitability for human or animal application.
Purpose and Limitations: The product is intended exclusively for laboratory research. It is not intended for human or animal application, diagnosis, treatment, alleviation, or prevention of diseases. The description is not medical advice. The designation of research use and package name do not themselves determine the regulatory status of the product or prove its safety or sterility.
COA on request
To enquire about a certificate of analysis (COA), send the material name, requested variant and LOT / batch number if available. Documents are not published on this page.
Request a COA by emailThe button opens your email app with a prepared enquiry. You send the message yourself. peptivacomhr@gmail.com
A COA applies to a specific batch. A purity result alone does not establish sterility, absence of endotoxins or safety for use in humans or animals.